MannKind Corp (OQ:MNKD)

Apr 03, 2024 06:00 am ET
MannKind Repays Certain Debt Obligations
MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that it has repaid in full all...
Mar 26, 2024 04:05 pm ET
MannKind Announces CFO Transition
MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that Steven B. Binder will retire from...
Mar 11, 2024 06:05 am ET
INHALE-3 Study’s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections (MDI) and Insulin Pumps
MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced initial meal challenge data from INHALE-3...
Mar 05, 2024 06:05 am ET
MannKind Announces New Clinical Data From Inhale-3 Study to be Presented by Dr. Irl B. Hirsch at ATTD on March 8
MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that new clinical data from the...
Mar 04, 2024 01:01 pm ET
MannKind Corporation Announces Participation at Upcoming Conferences
MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that it will be participating at...
Feb 27, 2024 04:00 pm ET
MannKind Corporation Reports 2023 Fourth Quarter and Full Year Financial Results: Provides Clinical Development Update
MannKind Corporation (Nasdaq: MNKD) today reported financial results for the quarter and full year ended December 31, 2023. “We doubled our total revenues to nearly $200 million in 2023 and ended the year with a robust fourth quarter total...
Feb 20, 2024 06:00 am ET
MannKind Corporation to Hold 2023 Fourth Quarter and Full Year Financial Results Conference Call on February 27, 2024
MannKind Corporation (Nasdaq: MNKD) will release its 2023 fourth quarter and full year financial results and its management will host a conference call to discuss these results and corporate updates at 5:00 PM (Eastern Time) on Tuesday, February...
Feb 15, 2024 06:05 am ET
MannKind Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza®
MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that it has fully enrolled 305 patients living...
Jan 02, 2024 06:05 am ET
MannKind and Sagard Healthcare Enter Into Royalty Purchase Agreement for Up to $200 Million
MannKind Corporation (Nasdaq: MNKD) announced that on December 27, 2023 it sold a 1% royalty in net sales of Tyvaso DPI® (treprostinil) inhalation powder in exchange for up to $200 million, including the purchase price of $150 million and an...
Dec 28, 2023 06:00 am ET
MannKind Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference
MannKind Corporation (Nasdaq: MNKD) a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer, Michael Castagna,...
Nov 07, 2023 04:00 pm ET
MannKind Corporation Reports 2023 Third Quarter Financial Results
MannKind Corporation (Nasdaq: MNKD) today reported financial results for the quarter ended September 30, 2023. “We had another strong quarter of revenue growth with total revenues exceeding $51 million,” said Michael Castagna, PharmD, Chief...
Nov 06, 2023 06:15 am ET
MannKind Announces Completion of Enrollment in U.S. Phase 4 Inhale-3 Clinical Trial in Patients Living With Type 1 Diabetes
MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that it has fully enrolled patients in...
Oct 31, 2023 04:00 pm ET
MannKind Corporation to Hold 2023 Third Quarter Financial Results Conference Call on November 7, 2023
MannKind Corporation (Nasdaq: MNKD) will release its 2023 third quarter financial results and year to date financial results and its management will host a conference call to discuss these results and corporate updates at 5:00 PM (Eastern Time) on...
Oct 30, 2023 06:15 am ET
MannKind Expands Patent Portfolio With New Clofazimine Formulation Patent
MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, today announced a new patent (No. 11,793,808) issued...
Sep 05, 2023 06:00 am ET
MannKind Corporation Announces Participation at Upcoming Conferences
MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that it will be participating at...
Aug 07, 2023 04:00 pm ET
MannKind Corporation Reports 2023 Second Quarter Financial Results
MannKind Corporation (Nasdaq: MNKD) today reported financial results for the quarter ended June 30, 2023. “We are excited to report positive income from operations in the second quarter driven by growing patient demand for Tyvaso DPI® and Afrezza...
Aug 01, 2023 06:00 am ET
MannKind Corporation Announces Participation in the 2023 Wedbush PacGrow Healthcare Conference
MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer,...
Jul 31, 2023 04:00 pm ET
MannKind Corporation to Hold 2023 Second Quarter Financial Results Conference Call on August 7, 2023
MannKind Corporation (Nasdaq: MNKD) will release its 2023 second quarter financial results and year to date financial results and its management will host a conference call to discuss these results and corporate updates at 5:00 PM (Eastern Time) on...
Jun 22, 2023 06:05 am ET
MannKind Launches Inhale-3 Study to Address the Most Important Unmet Need Today in Adults Living With Type 1 Diabetes (T1D)
MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that it is launching the INHALE-3...
Jun 11, 2023 08:05 am ET
Governor Ned Lamont to Tour MannKind June 12 as It Reaches a Manufacturing Milestone
MannKind Corporation (Nasdaq: MNKD) will host Connecticut Governor Ned Lamont for a tour of its headquarters on Monday, June 12. The visit coincides with MannKind reaching a manufacturing milestone as it has successfully scaled-up operations for...
May 24, 2023 08:30 am ET
Dr. Burkhard Blank Joins MannKind as Executive Vice President of Research & Development and Chief Medical Officer
MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced Burkhard Blank, MD, has joined the company...
May 10, 2023 06:00 am ET
MannKind Corporation to Participate in the 2023 RBC Capital Markets Global Healthcare Conference
MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer,...
May 09, 2023 08:21 pm ET
CORRECTION -- MannKind Corporation Reports 2023 First Quarter Financial Results
In a release issued under the same headline earlier today by MannKind Corporation (Nasdaq: MKND), please note in the second table, titled "CONDENSED CONSOLIDATED BALANCE SHEETS", the right column header was incorrectly labeled as "March 31, 2022",...
May 09, 2023 04:00 pm ET
Mannkind Corporation Reports 2023 First Quarter Financial Results
MannKind Corporation (Nasdaq: MNKD) today reported financial results for the quarter ended March 31, 2023. “Demand for Tyvaso DPI® has been very strong, which resulted in $23 million in revenues in the first quarter of 2023,” said Michael...
May 02, 2023 05:00 pm ET
MannKind Corporation to Hold 2023 First Quarter Financial Results Conference Call on May 9, 2023
MannKind Corporation (Nasdaq: MNKD) will release its 2023 first quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on Tuesday, May 9, 2023....
Mar 27, 2023 04:05 pm ET
Lauren Sabella Joins Mannkind as Executive Vice President, Chief Operating Officer
MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced Lauren Sabella has joined the company as...
Mar 07, 2023 05:00 pm ET
MannKind Corporation to Participate in Oppenheimer 33rd Annual Healthcare Conference
MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer,...
Feb 24, 2023 09:56 am ET
Thinking about buying stock in Timber Pharmaceuticals, Warner Bros, Alibaba, MannKind, or ON Semiconductor?
NEW YORK, Feb. 24, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TMBR, WBD, BABA, MNKD, and ON.
Feb 23, 2023 04:00 pm ET
MannKind Corporation Reports 2022 Fourth Quarter and Full Year Financial Results
MannKind Corporation (Nasdaq: MNKD) today reported financial results for the fourth quarter and full year ended December 31, 2022. “For 2022, we recognized almost $100 million in total revenues – an incredible triumph for our entire...
Feb 22, 2023 06:05 am ET
MannKind to Give Oral Presentation on Meal Challenge Results From the Afrezza® With Basal Combination (ABC Study) at 16th Annual ATTD Conference
MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that it will present an oral...
Feb 16, 2023 05:00 pm ET
MannKind Corporation to Hold 2022 Fourth Quarter and Full Year Financial Results Conference Call on February 23, 2023
MannKind Corporation (Nasdaq: MNKD) will release its 2022 fourth quarter and full year financial results and its management will host a conference call to discuss these results and corporate updates at 5:00 PM (Eastern Time) on Thursday, February...
Feb 10, 2023 05:00 pm ET
Mannkind Corporation to Participate in the SVB Securities Global Biopharma Conference
MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer,...
Jan 24, 2023 06:00 am ET
MannKind Corporation to Participate in the Lytham Partners Investor Select Conference
MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer,...
Jan 23, 2023 06:05 am ET
MannKind’s Inhaled Clofazimine Will Advance to an Adaptive Phase 2/3 Study For Potential Treatment of Rare Lung Disease
MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, today announced clofazimine inhalation suspension...
Jan 05, 2023 06:00 am ET
MannKind Corporation to Present at 2023 Annual J.P. Morgan Healthcare Conference
MannKind Corporation (Nasdaq: MNKD) a company focused on the development and commercialization of innovative therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer, Michael...
Nov 10, 2022 06:05 am ET
MannKind to Present Two Posters at 22nd Annual Diabetes Technology Meeting
MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that it will present data from two...
Nov 08, 2022 08:00 am ET
MannKind Corporation Reports 2022 Third Quarter Financial Results
MannKind Corporation (Nasdaq: MNKD) today reported financial results for the third quarter and nine months ended September 30, 2022. “In the third quarter, we grew total revenues by 48% over 2021 as our collaboration with United Therapeutics had...
Nov 01, 2022 06:00 am ET
MannKind Corporation to Hold 2022 Third Quarter Financial Results Conference Call on November 8, 2022
MannKind Corporation (Nasdaq: MNKD) will release its 2022 third quarter and year to date financial results and its management will host a conference call to discuss these results and corporate updates at 9:00 AM (Eastern Time) on Tuesday, November...
Sep 21, 2022 05:00 pm ET
MannKind Corporation to Participate in the Lytham Partners Fall 2022 Investor Conference
MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer, Michael...
Sep 06, 2022 06:15 am ET
Mannkind Successfully Completes Phase 1 Study of Inhaled Clofazimine
MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that it has successfully completed a Phase 1 study...
Sep 01, 2022 06:00 am ET
MannKind Corporation to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer, Michael...
Aug 09, 2022 04:00 pm ET
MannKind Corporation Reports 2022 Second Quarter Financial Results
MannKind Corporation (Nasdaq: MNKD) today reported financial results for the second quarter and first half of 2022. “In the second quarter, we achieved multiple milestones that position the Company for growth over the next decade,” said Michael...
Aug 02, 2022 06:00 am ET
MannKind Corporation to Hold 2022 Second Quarter Financial Results Conference Call on August 9, 2022
MannKind Corporation (Nasdaq: MNKD) will release its 2022 second quarter and year to date financial results and its management will host a conference call to discuss these results and corporate updates at 5:00 PM (Eastern Time) on Tuesday, August...
Aug 01, 2022 06:00 am ET
MannKind Corporation to Participate in the BTIG Biotechnology Conference
MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer, Michael...
Jun 03, 2022 10:00 am ET
Mannkind to Host Product Theater and Booth at the American Diabetes Association’s 82nd Scientific Sessions in New Orleans, June 3-7
MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative therapeutic products for patients with endocrine and orphan lung diseases, will showcase its mealtime insulin solutions and expanding...
May 24, 2022 06:00 am ET
MannKind’s Technosphere® Inhalation Platform Utilized in FDA-Approved Tyvaso DPI™
MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative therapeutic products for patients with endocrine and orphan lung diseases, celebrated today that the U.S. Food and Drug Administration...
May 19, 2022 06:00 am ET
MannKind Corporation to Ring the Nasdaq Stock Market Opening Bell
MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer, Michael...
May 17, 2022 06:06 am ET
MannKind Corporation Announces Agreement to Acquire V-Go® Insulin Delivery Device From Zealand Pharma
MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of therapeutic products for people living with endocrine and orphan lung diseases, today announced that it has entered into an agreement with Zealand...
May 09, 2022 06:00 am ET
MannKind Corporation Participating at Upcoming Conferences
MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that it will be participating at upcoming...
May 05, 2022 04:00 pm ET
MannKind Corporation Reports 2022 First Quarter Financial Results
MannKind Corporation (Nasdaq: MNKD) today reported financial results for the quarter ended March 31, 2022. “As we approach the FDA action date for Tyvaso DPI, our company is focused on supporting United Therapeutics in their planned commercial...
Apr 28, 2022 06:00 am ET
MannKind Corporation to Hold 2022 First Quarter Financial Results Conference Call on May 5, 2022
MannKind Corporation (Nasdaq: MNKD) will release its 2022 first quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on Thursday, May 5, 2022....
Apr 27, 2022 06:05 am ET
MannKind Presents Poster at 15th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2022) to Be Held April 27-30
MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that it has presented a poster [Abstract #445] at...
Mar 28, 2022 06:05 am ET
MannKind Corporation to Participate in the Lytham Partners Spring 2022 Investor Conference
MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer, Michael...
Mar 22, 2022 06:05 am ET
MannKind Corporation to Participate in the Cantor Virtual Rare Orphan Disease Summit
MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Scientific Officer, Thomas Hofmann,...
Mar 08, 2022 06:05 am ET
MannKind Corporation to Participate in Oppenheimer 32nd Annual Healthcare Conference
MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer, Michael...
Feb 24, 2022 04:00 pm ET
MannKind Corporation Reports 2021 Fourth Quarter and Full Year Financial Results
MannKind Corporation (Nasdaq: MNKD) today reported financial results for the fourth quarter and full year ended December 31, 2021. “We had a solid fourth quarter with Afrezza net revenue hitting a record $11.3 million and we ended the year with...
Feb 24, 2022 06:05 am ET
Update on Tyvaso DPI™ New Drug Application
MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, was informed that the U.S. Food and Drug Administration (FDA)...
Feb 21, 2022 09:05 am ET
MannKind Corporation to Hold 2021 Fourth Quarter and Full Year Financial Results Conference Call on February 24, 2022
MannKind Corporation (Nasdaq: MNKD) will release its 2021 fourth quarter and full year financial results, and its management will host a conference call to discuss the financial results and corporate updates at 5:00 p.m. (Eastern Time) on Thursday,...
Feb 10, 2022 06:05 am ET
MannKind Corporation to Participate in SVB Leerink 2022 Global Healthcare Conference
MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer, Michael...
Jan 05, 2022 06:10 am ET
MannKind Corporation to Participate in H.C. Wainwright Bioconnect Conference
MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer Michael Castagna,...
Jan 05, 2022 06:05 am ET
MannKind Extends Collaboration With Thirona Bio on Fibrotic Lung Diseases
MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced that has extended its collaboration with Thirona Bio,...
Dec 06, 2021 06:05 am ET
MannKind Corporation to Participate in the Lytham Partners Winter 2021 Investor Conference
MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that it will be participating in the Lytham...
Nov 09, 2021 04:05 pm ET
MannKind Corporation Reports 2021 Third Quarter Financial Results
MannKind Corporation (Nasdaq: MNKD) today reported financial results for the quarter and nine months ended September 30, 2021. “The MannKind team continues to stay focused and execute our corporate objectives of preparing for the commercial launch...
Nov 09, 2021 06:05 am ET
Mannkind Corporation Closes Sale-Leaseback Transaction Generating $102.25 Million in Non-Dilutive Gross Proceeds
MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced the closing on November 8, 2021, of its previously...
Nov 05, 2021 07:05 am ET
MannKind Presents Data at 21st Annual Diabetes Technology Meeting
MannKind Corporation (Nasdaq: MNKD), which focuses on the development of innovative medicines for patients with endocrine and orphan lung diseases, will present data at the 21st Annual Diabetes Technology Meeting. The data is currently available...
Nov 02, 2021 06:05 am ET
MannKind Corporation to Hold 2021 Third Quarter Financial Results Conference Call on November 9, 2021
MannKind Corporation (Nasdaq:MNKD) will release its 2021 third quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on Tuesday, November 9, 2021....
Oct 18, 2021 06:00 am ET
Progress Update on Tyvaso DPI™ New Drug Application
MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, has learned that the U.S. Food and Drug Administration (FDA)...
Oct 04, 2021 07:05 am ET
MannKind Announces First Patient Enrolled In Inhale-1 Study Of Afrezza® In Pediatric Population
WESTLAKE VILLAGE, Calif., Oct. 4, 2021 /PRNewswire/ -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today the enrollment of the first pediatric patient in the INHALE-1 study. The multi-center study will evaluate the efficacy and safety of Afrezza® (Technosphere Insulin) in combination with basal insulin vs. multiple daily injections of insulin in children and adolescents aged 4-17 who are living with type 1 or type 2 diabetes.
Oct 04, 2021 07:05 am ET
MannKind Announces First Patient Enrolled in INHALE-1 Study of Afrezza® in Pediatric Population
MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today the enrollment of the first pediatric patient in...
Sep 29, 2021 04:24 pm ET
Mannkind Corporation Announces Sale-Leaseback Transaction Generating $102.25 Million in Non-Dilutive Gross Proceeds
MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that it has entered into a sale-leaseback...
Sep 28, 2021 06:05 am ET
MannKind Corporation to Participate at Lytham Partners Fall 2021 Investor Conference
MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that it will be participating at the Lytham...
Sep 15, 2021 06:05 am ET
Mannkind Corporation Participating at Upcoming Conferences
MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that it will be participating at upcoming...
Sep 07, 2021 06:05 am ET
MannKind Corporation to Participate in H.C. Wainwright 23rd Annual Global Investment Conference
MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer Michael Castagna,...
Sep 07, 2021 06:00 am ET
United Therapeutics Presents Tyvaso DPI™ BREEZE Clinical Data At The European Respiratory Society International Congress 2021
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Sept. 7, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today presented new clinical data from the BREEZE study evaluating Tyvaso DPI™ (treprostinil) in patients with pulmonary arterial hypertension (PAH) at the European Respiratory Society (ERS) International Congress 2021.
Aug 11, 2021 04:00 pm ET
MannKind Corporation Reports 2021 Second Quarter Financial Results
MannKind Corporation (Nasdaq:MNKD) today reported financial results for the quarter and six months ended June 30, 2021. “I am really proud of how our team has executed so far in 2021 supporting the growth of Afrezza and preparing for the potential...
Aug 04, 2021 06:48 am ET
MannKind Partners With NRx Pharmaceuticals To Explore A Dry Powder Formulation Of ZYESAMI™ (aviptadil) Based On The Technosphere® Platform
WESTLAKE VILLAGE, Calif., Aug. 4, 2021 /PRNewswire/ -- MannKind Corporation (Nasdaq: MNKD) has partnered with NRx Pharmaceuticals (Nasdaq: NRXP) (NRx) to evaluate the feasibility of formulating a dry powder formulation of ZYESAMI™ (aviptadil), a synthetic form of human Vasoactive Intestinal Peptide (VIP) – an endogenous substance produced by the body that helps protect cells against inflammatory conditions.  An intravenous formulation of ZYESAMI is currently in clinical trials, having been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) for the treatment of Crit
Aug 04, 2021 06:48 am ET
NRx Pharmaceuticals Partners with MannKind Corporation to Develop ZYESAMI™ (aviptadil) Inhaler for Respiratory Conditions
RADNOR, Pa., Aug. 4, 2021 /PRNewswire/ -- NRx Pharmaceuticals (NRx) (Nasdaq: NRXP) announced today it has signed an agreement with MannKind Corporation to develop a dry powder formulation of ZYESAMI™ (aviptadil), a synthetic form of human Vasoactive Intestinal Peptide (VIP), produced by the body to help protect cells against inflammatory conditions. Development will be based on MannKind's proven Technosphere® platform, that is the basis of the US Food and Drug Administration (FDA) -approved Afrezza® inhaled insulin product.
Aug 04, 2021 06:15 am ET
MannKind Corporation to Hold 2021 Second Quarter Financial Results Conference Call on August 11, 2021
MannKind Corporation (Nasdaq:MNKD) will release its 2021 second quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on Wednesday, August 11, 2021....
Aug 03, 2021 09:00 am ET
MannKind Corporation to Participate in the BTIG Virtual Biotechnology Conference 2021
MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer, Michael...
Jul 29, 2021 11:00 am ET
INDYCAR Driver Conor Daly To Share His Personal Diabetes Story And Race Go-Karts With Local Youth On Wednesday, August 4th
WESTLAKE VILLAGE, Calif., July 29, 2021 /PRNewswire/ -- MannKind Corporation (Nasdaq: MNKD) will team up with NTT INDYCAR SERIES driver Conor Daly, who is living with Type 1 diabetes (T1D) for a one-of-a-kind experience with local youth and families as part of Music City Grand Prix week. Daly will share his personal story of being diagnosed with diabetes as a teen and how he does not let it keep him from living life without limits. The former karting champion will also provide some karting tips and then race go-karts to identify the Fastest 6.
Jun 28, 2021 08:30 am ET
Thinking about buying stock in Anavex Life Sciences, Arbutus Biopharma, MannKind, Perion Network, or Precision BioSciences?
NEW YORK, June 28, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AVXL, ABUS, MNKD, PERI, and DTIL.
Jun 28, 2021 06:15 am ET
Policy Change Allows Approval For Medicare Patients Living With Diabetes To Use Both Afrezza® And Continuous Glucose Monitoring Devices Beginning July 18
WESTLAKE VILLAGE, Calif., June 28, 2021 /PRNewswire/ -- MannKind Corporation (Nasdaq: MNKD) appreciates the recent efforts of the Centers for Medicare and Medicaid Services (CMS) in conjunction with the Medicare Administration Contractors (MACs) to implement a policy change to the Local Coverage Determination (LCD) L33822, allowing the approval to Medicare patients living with diabetes to select both Afrezza® and Continuous Glucose Monitors (CGMs). Effective July 18, the criteria change lifts the restriction on patients of having to choose between the two diabetes tools.
Jun 25, 2021 11:35 am ET
MannKind Presents Two Posters At American Diabetes Association's Virtual 81st Scientific Sessions, June 25-29
WESTLAKE VILLAGE, Calif., June 25, 2021 /PRNewswire/ -- MannKind Corporation (Nasdaq: MNKD), which focuses on the development of innovative medicines for patients with endocrine and orphan lung diseases, will present two posters at the American Diabetes Association's virtual 81st Scientific Sessions, June 25-29.  The submissions include 923-P in Pediatrics-Type 1 Diabetes, and 722-P in Clinical Therapeutics/New Technology-Insulins.  MannKind is also hosting a booth in the virtual Exhibit Hall at the Scientific Sessions.
Jun 16, 2021 10:59 am ET
MannKind And United Therapeutics Achieve A Major Milestone In The Development Of Tyvaso DPI™ With New Drug Application Acceptance From The FDA
DANBURY, Conn., June 16, 2021 /PRNewswire/ -- MannKind Corporation (Nasdaq: MNKD) and United Therapeutics Corporation (Nasdaq: UTHR) reached a major milestone today with the announcement that the U.S. Food and Drug Administration (FDA) accepted for priority review of the New Drug Application (NDA) for Tyvaso DPI™ (inhaled treprostinil) for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The development marks the second compound formulated with MannKind's Technosphere® technology to be reviewed by the FDA, w
Jun 16, 2021 08:32 am ET
Thinking about buying stock in Catabasis Pharmaceuticals, Arrival, MannKind, Trevena, or Altimmune?
NEW YORK, June 16, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CATB, ARVL, MNKD, TRVN, and ALT.
Jun 16, 2021 06:15 am ET
MannKind and United Therapeutics Achieve a Major Milestone in the Development of Tyvaso DPI™ With New Drug Application Acceptance From the FDA
MannKind Corporation (Nasdaq: MNKD) and United Therapeutics Corporation (Nasdaq: UTHR) reached a major milestone today with the announcement that the U.S. Food and Drug Administration (FDA) accepted for priority review of the New Drug Application...
Jun 16, 2021 06:00 am ET
United Therapeutics Announces FDA Acceptance of Tyvaso DPI™ New Drug Application For Priority Review
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., June 16, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced that the U.S. Food and Drug Administration (FDA) accepted for priority review the New Drug Application (NDA) for Tyvaso DPI™ (inhaled treprostinil) for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). United Therapeutics expects the agency's review to be complete in October 2021. FDA also indicated that they have not identified any potential review issues at this t
Jun 10, 2021 06:15 am ET
MannKind and Thirona Bio Join Forces to Evaluate Potential Inhaled Therapy for Fibrotic Lung Diseases
MannKind Corporation (Nasdaq: MNKD) and Thirona Bio, Inc. today announced that they have entered into a transaction that is intended to advance the development of a novel compound with potential for multiple indications. FBM5712 is a novel small...
Jun 08, 2021 05:00 pm ET
MannKind Corporation at the Lytham Partners Summer 2021 Investor Conference
MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer, Michael...
May 13, 2021 09:00 am ET
MannKind Announces Partnership With Type 1 Diabetes IndyCar Driver Conor Daly
MannKind Corporation (Nasdaq: MNKD) is revved up to announce an elevated partnership for the 2021 season with NTT INDYCAR SERIES driver Conor Daly, who is living with Type 1 diabetes (T1D) and will help raise awareness about diabetes and innovative...
May 12, 2021 04:00 pm ET
MannKind Corporation Reports 2021 First Quarter Financial Results
MannKind Corporation (Nasdaq:MNKD) today reported financial results for the quarter ended March 31, 2021. “We started 2021 by taking advantage of favorable market conditions to strengthen our financial position with the issuance of $230 million...
May 11, 2021 09:00 am ET
MannKind Corporation to Participate in 2021 RBC Capital Markets Global Healthcare Conference
MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer, Michael...
May 05, 2021 09:00 am ET
MannKind Corporation to Hold 2021 First Quarter Financial Results Conference Call on May 12, 2021
MannKind Corporation (Nasdaq:MNKD) will release its 2021 first quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on Wednesday, May 12, 2021....
Apr 26, 2021 09:00 am ET
MannKind Reduces Legacy Debt by Approximately $49.5 Million and Restructures Remaining Obligations, including Extended Maturity, Lower Interest Rates and Increased Third Tranche
MannKind Corporation (Nasdaq: MNKD) announced that on April 22, 2021 it and MidCap Financial Trust, as agent, entered into an amendment of the credit and security agreement dated August 6, 2019 (the “MidCap Credit Facility”). In addition, MannKind...
Apr 19, 2021 06:00 am ET
Mannkind and United Therapeutics Reach a Milestone in the Development of Tyvaso DPI™ With New Drug Application Submitted to the FDA
MannKind Corporation (Nasdaq: MNKD) and United Therapeutics (Nasdaq: UTHR) reached a milestone today in the development of Tyvaso DPI™ as United Therapeutics submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA)....
Mar 16, 2021 09:00 am ET
MannKind Announces Closing of Initial Purchasers’ Option to Purchase Additional Convertible Senior Notes
MannKind Corporation (Nasdaq: MNKD) today announced that on March 15, 2021 it issued an additional $30.0 million aggregate principal amount of 2.50% Convertible Senior Notes due 2026 (the "notes") pursuant to the exercise in full of the initial...
Mar 15, 2021 08:00 am ET
MannKind to Participate in 2022 Medicare Part D Senior Savings Model to Make Insulin More Affordable for Seniors
MannKind Corporation (Nasdaq: MNKD), announced today that it will participate in the 2022 Medicare Part D Senior Savings Model, which is intended to improve the affordability of insulin for Medicare beneficiaries by capping the co-pay per 30-day...
Mar 10, 2021 05:00 pm ET
MannKind Corporation to Participate in Oppenheimer's 31st Annual Healthcare Conference
MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer, Michael...
Mar 02, 2021 05:00 pm ET
MannKind Corporation to Participate in H.C. Wainwright Global Life Sciences Conference
MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer, Michael...
Mar 02, 2021 06:30 am ET
MannKind Corporation Prices Upsized $200.0 Million Convertible Senior Notes Offering
MannKind Corporation (Nasdaq: MNKD) today announced the pricing of $200.0 million aggregate principal amount of 2.50% Convertible Senior Notes due 2026 (the "notes") in a private placement (the "offering") to qualified institutional buyers pursuant...
Mar 01, 2021 07:00 am ET
MannKind Corporation Announces Proposed Private Placement of Convertible Senior Notes
MannKind Corporation (NASDAQ:MNKD) today announced that it intends to offer, subject to market conditions and other factors, $150.0 million aggregate principal amount of Convertible Senior Notes due 2026 (the "notes") in a private placement (the...
Feb 25, 2021 08:00 am ET
MannKind Corporation Reports 2020 Fourth Quarter and Full Year Financial Results
MannKind Corporation (NASDAQ:MNKD) today reported financial results for the fourth quarter and full year ended December 31, 2020. “Our fourth quarter produced exceptional results, with $10.1 million in Afrezza net revenue and positive clinical...
Feb 24, 2021 07:00 am ET
Vertice launches THYQUIDITY™ (levothyroxine sodium) Oral Solution
NEW PROVIDENCE, N.J., Feb. 24, 2021 /PRNewswire/ -- Vertice Pharma ("Vertice"), a specialty pharmaceuticals company focused on improving patients' health, today announced the launch of THYQUIDITY. THYQUIDITY is indicated as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism and as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.*
Feb 18, 2021 05:00 pm ET
MannKind Corporation to Participate in 2021 SVB Leerink Global Healthcare Conference
MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer, Michael...
Feb 18, 2021 09:00 am ET
MannKind Corporation to Hold 2020 Fourth Quarter and Full Year Financial Results Conference Call on February 25, 2021
MannKind Corporation (NASDAQ:MNKD) will release its 2020 fourth quarter and full year financial results and its management will host a conference call to discuss the financial results and corporate updates at 9:00 AM (Eastern Time) on Thursday,...
Jan 04, 2021 05:00 pm ET
MannKind Corporation to Participate in H.C. Wainwright Bioconnect 2021 Conference
MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer, Michael...
Dec 17, 2020 04:43 pm ET
MannKind and Vertice to Co-Promote Thyquidity™ (levothyroxine sodium) Oral Solution
MannKind Corporation (Nasdaq: MNKD) and Vertice Pharma today announced that they have entered into a co-promotion agreement for Thyquidity™ (levothyroxine sodium) oral solution through MannKind’s specialty sales force. THYQUIDITY is indicated as a...
Dec 10, 2020 08:00 am ET
James S. Shannon Transitions to Chairman of the Board of Directors for MannKind
MannKind Corporation (Nasdaq: MNKD) today announced that James S. Shannon, M.D., MRCP (UK) has been named the new Chairman of the Board of Directors effective December 9, 2020. Kent Kresa, the former Chairman of the Board, will continue to serve on...
Dec 07, 2020 09:20 am ET
MannKind Expands Its Pipeline with the Acquisition of QrumPharma, Inc.
MannKind Corporation (Nasdaq: MNKD) today announced that it has acquired QrumPharma, Inc., a privately held pharmaceutical company developing inhalation treatments for severe chronic and recurrent pulmonary infections, including Nontuberculous...
Dec 01, 2020 08:00 am ET
MannKind and MidCap Amend Credit Facility
MannKind Corporation (Nasdaq: MNKD) today announced that it and MidCap Financial Trust, as agent, have entered into an amendment to the credit and security agreement dated August 6, 2019 (the “MidCap Credit Facility”). “We appreciate the...
Nov 30, 2020 08:00 am ET
Sabrina Kay Appointed to MannKind Board of Directors
MannKind Corporation (NASDAQ:MNKD) today announced that Sabrina Kay Ed.D. has been appointed to its Board of Directors, effective December 1, 2020. Dr.  Kay will also serve as a member of the Audit Committee of the Board. A serial entrepreneur,...
Nov 19, 2020 05:00 pm ET
MannKind Receives Fourth $12.5 Million Milestone Payment from United Therapeutics
MannKind Corporation (NASDAQ:MNKD) today announced that it has achieved the final development milestone under its licensing and collaboration agreement with United Therapeutics for the development and commercialization of a dry powder formulation...
Nov 10, 2020 09:15 am ET
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating MannKind Corporation for Potential Breaches of Fiduciary Duty By Its Board of Directors
NEW YORK, Nov. 10, 2020 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of MannKind Corporation (NASDAQ: MNKD).
Nov 04, 2020 04:00 pm ET
MannKind Corporation Reports 2020 Third Quarter Financial Results
MannKind Corporation (NASDAQ:MNKD) today reported financial results for the quarter and nine months ended September 30, 2020. “Our employees continue to execute in a tumultuous Covid-19 environment,” said Michael Castagna, Chief Executive Officer....
Oct 29, 2020 08:00 am ET
MannKind Corporation to Hold 2020 Third Quarter Financial Results Conference Call on November 4, 2020
MannKind Corporation (NASDAQ:MNKD) will release its 2020 third quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on Wednesday, November 4, 2020....
Sep 08, 2020 08:00 am ET
MannKind Corporation Participating at Upcoming Conferences
MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diabetes and orphan lung diseases, announced today that it will be participating at upcoming...
Aug 31, 2020 09:00 am ET
Kevin Kaiserman Joins MannKind as Vice President, Medical Affairs and Safety
MannKind Corporation (NASDAQ: MNKD) today announced that Kevin Kaiserman, MD, has joined the company as Vice President, Medical Affairs and Safety and will assume full responsibility for leading MannKind’s medical affairs, field medical activities,...
Aug 07, 2020 05:00 pm ET
MannKind Corporation to Participate in BTIG Virtual Biotechnology Conference 2020
MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diabetes and orphan lung diseases, announced today that its Chief Executive Officer, Michael Castagna,...
Aug 05, 2020 04:00 pm ET
MannKind Corporation Reports 2020 Second Quarter Financial Results
MannKind Corporation (NASDAQ:MNKD) today reported financial results for the quarter and six months ended June 30, 2020. “I am proud of how our employees pulled together during these uncertain times and innovated as a team to minimize the...
Jul 29, 2020 05:00 pm ET
MannKind Corporation to Hold 2020 Second Quarter Financial Results Conference Call on August 5, 2020
MannKind Corporation (NASDAQ:MNKD) will release its 2020 second quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on Wednesday, August 5, 2020....
Jul 20, 2020 09:00 am ET
Alejandro Galindo Joins MannKind as Chief Commercial Officer
MannKind Corporation (NASDAQ: MNKD) today announced that effective August 4, 2020, Alejandro Galindo, M.B.A, M.S., will be leading MannKind’s commercial operations as Chief Commercial Officer. Mr. Galindo will report directly to Michael Castagna,...
Jun 17, 2020 05:00 pm ET
MannKind Corporation to Present at the June 2020 Lytham Partners Virtual Investor Growth Conference
MannKind Corporation (NASDAQ:MNKD) announced today that it will be featured in a virtual presentation and fireside chat at the June 2020 Lytham Partners Virtual Investor Growth Conference on Wednesday, June 24, 2020 at 12 pm ET (9 am PT)....
Jun 15, 2020 09:00 am ET
MannKind Presents Positive Original Analyses of Afrezza® Clinical Data at  American Diabetes Association (ADA) 80th Scientific Sessions
MannKind Corporation (Nasdaq: MNKD) announced that new data from clinical studies of Afrezza® (insulin human) Inhalation Powder was presented at the American Diabetes Association’s 80th Scientific Sessions, June 12-16, 2020. The data presented...
Jun 13, 2020 12:00 pm ET
Investigator-Initiated Study Shows Switching to Afrezza® Improves Glucose Control with No Additional Hypoglycemia in T2DM
MannKind Corporation (Nasdaq: MNKD) announced that data from a new clinical study of Afrezza® (insulin human) Inhalation Powder will be presented at the American Diabetes Association’s 80th Scientific Sessions during the ePoster session (Poster...
May 06, 2020 04:00 pm ET
MannKind Corporation Reports 2020 First Quarter Financial Results
MannKind Corporation (NASDAQ:MNKD) today reported financial results for the quarter ended March 31, 2020. “We are pleased to report first quarter Afrezza net revenue of $8.0 million, which is 58% higher than the same quarter in 2019,” said Michael...
Apr 29, 2020 05:00 pm ET
MannKind Corporation to Hold 2020 First Quarter Financial Results Conference Call on May 6, 2020
MannKind Corporation (NASDAQ:MNKD) will release its 2020 first quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on Wednesday, May 6, 2020....
Apr 15, 2020 08:00 am ET
MannKind Receives Forgivable Loan under the Paycheck Protection Program
MannKind Corporation (NASDAQ:MNKD) today announced that it received a loan of approximately $4.9 million from JPMorgan Chase Bank, N.A., as lender, pursuant to the Paycheck Protection Program (“PPP”) of the Coronavirus Aid, Relief, and Economic...
Mar 24, 2020 09:00 am ET
Jennifer Grancio Appointed to MannKind Board of Directors
MannKind Corporation (NASDAQ:MNKD) today announced that Jennifer Grancio has been appointed to its Board of Directors, effective March 23, 2020. Ms. Grancio will also serve as a member of the Audit Committee of the Board. Ms. Grancio brings to...
Mar 17, 2020 09:00 am ET
MannKind Refocuses Pipeline Resources in Response to COVID-19 Pandemic
MannKind Corporation (NASDAQ: MNKD), a company focused on the development and commercialization of inhaled therapeutic products, today announced that it is adjusting research and development resources that were reserved for its pipeline of...
Feb 25, 2020 08:00 am ET
MannKind Corporation Reports 2019 Fourth Quarter and Full Year Financial Results
MannKind Corporation (NASDAQ:MNKD) today reported financial results for the fourth quarter and full year ended December 31, 2019. “We ended 2019 on a strong note with fourth quarter 2019 Afrezza net revenue of $7.8 million, our best...
Feb 24, 2020 06:25 pm ET
MannKind Corporation to Present at the 9th Annual SVB Leerink Global Healthcare Conference
MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, announced today that it will be...
Feb 20, 2020 09:00 am ET
MannKind Presents Novel Scientific Data at 13th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2020)
MannKind Corporation (NASDAQ: MNKD) today announced the presentation of results from multiple clinical studies of Afrezza® (insulin human) Inhalation Powder and MannKind’s BluHale® technology system. These data are being presented in both oral and...
Feb 18, 2020 09:00 am ET
MannKind Corporation to Hold 2019 Fourth Quarter and Full Year Financial Results Conference Call on February 25, 2020
MannKind Corporation (NASDAQ:MNKD) will release its 2019 fourth quarter and full year financial results and its management will host a conference call to discuss the financial results and corporate updates at 9:00 AM (Eastern Time) on Tuesday,...
Jan 06, 2020 08:00 am ET
Afrezza® (insulin human) Inhalation Powder Receives Pricing Registration in Brazil Commercial activities to commence this month
MannKind Corporation (NASDAQ: MNKD) announced today that its Brazilian partner, Biomm S.A., has received written notice from the Chamber of Regulation of the Medicines Market (CMED) approving the proposed price of Afrezza in Brazil. Biomm intends...
Dec 20, 2019 09:00 am ET
Study 171 Shows Hypoglycemia is Reduced with Use of Afrezza® Relative to Insulin Aspart in Type 1 Diabetes
MannKind Corporation (NASDAQ: MNKD) announced today that Hypoglycemia is reduced with use of inhaled Technosphere® Insulin relative to insulin aspart in type 1 diabetes mellitus has been published online in DIABETICMedicine. This post-hoc analysis...
Nov 29, 2019 09:00 am ET
MannKind Corporation to Present at the Piper Jaffray 31st Annual Healthcare Conference
MannKind Corporation (NASDAQ: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, announced today that it will be...
Nov 21, 2019 09:00 am ET
MannKind Appoints Tony Hooper to Its Board of Directors
MannKind Corporation (NASDAQ:MNKD) today announced that Anthony Hooper will join its Board of Directors, effective January 1, 2020.  Mr. Hooper will also serve as a member of the Audit Committee of the Board. Mr. Hooper brings 35 years of...
Nov 06, 2019 08:00 am ET
MannKind Corporation Reports 2019 Third Quarter Preliminary Financial Results
MannKind Corporation (NASDAQ:MNKD) today reported preliminary financial results for the quarter and nine months ended September 30, 2019. “I am excited to see MannKind continue its transformation, with another quarter of double-digit growth in...
Nov 04, 2019 09:00 am ET
MannKind Receives Second $12.5 Million Milestone Payment From United Therapeutics
MannKind Corporation (NASDAQ: MNKD) today announced that it has achieved the second of four specified development milestones under its licensing and collaboration agreement with United Therapeutics for the development and commercialization of a dry...
Oct 30, 2019 09:00 am ET
MannKind Corporation to Hold 2019 Third Quarter Financial Results Conference Call on November 6, 2019
MannKind Corporation (NASDAQ:MNKD) will release its 2019 third quarter and year-to-date financial results and its management will host a conference call to discuss the financial results and corporate updates at 9:00 AM (Eastern Time) on Wednesday,...
Sep 26, 2019 09:00 am ET
MannKind Corporation to Present at the 2019 Cantor Global Healthcare Conference
MannKind Corporation (NASDAQ: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, announced today that it will be...
Sep 19, 2019 09:00 am ET
MannKind Presents Positive Afrezza® Clinical Data from Type 1 Diabetes Study at 55th Annual Meeting of the EASD
MannKind Corporation (NASDAQ: MNKD) announced that data from a one-year study of Afrezza® (insulin human) Inhalation Powder was presented at the 55th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Barcelona, Spain....
Aug 30, 2019 09:00 am ET
MannKind Corporation to Present at H.C. Wainwright 21st Annual Global Investment Conference
MannKind Corporation (NASDAQ: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, announced today that it will be...
Aug 07, 2019 04:01 pm ET
MannKind Corporation Reports 2019 Second Quarter Financial Results and Recent Business Highlights
MannKind Corporation (NASDAQ:MNKD) today reported financial results for the quarter and six months ended June 30, 2019. “We continue to execute our commercial strategy for Afrezza, which resulted in product growth of 62% versus the second quarter...
Aug 05, 2019 09:00 am ET
MannKind and One Drop Sign Collaboration Agreement to Integrate Bluetooth-Connected Inhaler with Dose Detection into the One Drop Platform
MannKind Corporation (NASDAQ: MNKD) and One Drop today announced that they have signed a collaborative agreement that is intended to integrate MannKind’s BluHale® accessory device into the One Drop platform.  BluHale is a Bluetooth-connected...
Aug 01, 2019 05:02 pm ET
MannKind Corporation to Hold 2019 Second Quarter Financial Results Conference Call on August 7, 2019
MannKind Corporation (NASDAQ: MNKD) will release its 2019 second quarter and year-to-date financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on...
Jul 31, 2019 09:00 am ET
Afrezza® Safety and Pharmacokinetics Study in Pediatric Patients Opens Enrollment for Cohort 3
MannKind Corporation (NASDAQ:MNKD) announced today that the Afrezza® safety and pharmacokinetics study in pediatric patients is now enrolling children 4-7 years of age (Cohort 3) and nearing completion for Cohort 2 (8-12 years of age). An interim...
Jul 18, 2019 08:52 am ET
MannKind Repays Maturing Debt Obligation; Buys Back Certain Warrants
MannKind Corporation (NASDAQ: MNKD) today announced the repayment of outstanding debt by an aggregate amount of approximately $4.0 million and the repurchase of a warrant to purchase approximately 3.3 million shares of common stock.  The Company...
Jul 15, 2019 09:00 am ET
MannKind Partners with GoodRx to Help Raise Awareness on Reducing Out of Pocket Insulin Cost for Patients
MannKind Corporation (Nasdaq:MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, today announced that it has partnered...
Jul 11, 2019 04:14 pm ET
MannKind Expands Commercial Scale Manufacturing Capabilities for High-Potency Molecules
MannKind Corporation (Nasdaq:MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, announced that it has completed...
Jun 12, 2019 09:00 am ET
MannKind to Present at the JMP Securities Life Sciences Conference
MannKind Corporation (NASDAQ: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, announced today that it will be...
Jun 09, 2019 02:00 pm ET
MannKind Presents Positive Afrezza® Clinical Data from Three Studies at ADA 79th Scientific Sessions
MannKind Corporation (Nasdaq: MNKD) announced that new data from three different studies of Afrezza® (insulin human) Inhalation Powder were released at the American Diabetes Association’s 79th Scientific Sessions, being held June 7-11, in San...
Jun 03, 2019 08:00 am ET
Afrezza® (insulin human) Inhalation Powder Approved in Brazil
MannKind Corporation (Nasdaq:MNKD) and BIOMM SA (BVMF:BIOM3) today announced that Afrezza® (insulin human) Inhalation Powder, an ultra rapid-acting mealtime insulin to improve glycemic control in adult patients with diabetes mellitus, has been...
May 16, 2019 04:01 pm ET
MannKind Announces Afrezza® Distribution Agreement in Australia
MannKind Corporation (Nasdaq: MNKD) today announced that it has entered into an exclusive marketing and distribution agreement with the AMSL Diabetes division of Australasian Medical & Scientific Ltd. for the commercialization of Afrezza® (insulin...
May 07, 2019 08:00 am ET
MannKind Corporation Reports 2019 First Quarter Financial Results
MannKind Corporation (NASDAQ:MNKD) today reported financial results for the quarter ended March 31, 2019. “In the first quarter of 2019, we executed against the United Therapeutics License and Collaboration agreement, achieving the first of four...
Apr 30, 2019 09:00 am ET
MannKind Corporation to Hold 2019 First Quarter Financial Results Conference Call on May 7, 2019
MannKind Corporation (Nasdaq:MNKD) will release its 2019 first quarter financial results on Tuesday, May 7, 2019 and its management will host a conference call to discuss the financial results and other Company developments at 9:00 AM (Eastern...
Apr 25, 2019 09:45 am ET
MannKind Presents Scientific Data at 28th Annual Scientific and Clinical Congress of the American Association of Clinical Endocrinologists (AACE 2019)
MannKind Corporation (Nasdaq:MNKD) today announced additional data supporting the distinct clinical profile of Afrezza will be presented in an e-poster presentation on Thursday, April 25, 2019 at the 28th Annual Scientific and Clinical Congress of...
Apr 08, 2019 08:25 am ET
Detailed Research: Economic Perspectives on MannKind, Sonic Automotive, Five Prime Therapeutics, CONMED, Cohu, and FTI Consulting — What Drives Growth in Today's Competitive Landscape
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of MannKind Corporation (NASDAQ:MNKD), Sonic Automotive, Inc. (NYSE:SAH),...
Apr 02, 2019 06:00 am ET
MannKind to Present at the H.C. Wainwright Global Life Sciences Conference
MannKind Corporation (NASDAQ: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, announced today that it will be...
Apr 01, 2019 06:00 am ET
MannKind Receives $12.5 Million Milestone Payment from United Therapeutics
MannKind Corporation (NASDAQ: MNKD) today announced that it achieved the first of several specified development milestones under its licensing and collaboration agreement with United Therapeutics for the development and commercialization of a dry...
Mar 14, 2019 09:00 am ET
MannKind to Sponsor Andretti Autosport Type 1 Diabetes Driver, Conor Daly
MannKind Corporation (Nasdaq:MNKD) announced today it is sponsoring Conor Daly as he makes his debut with the Andretti Autosport team at the 103rd Running of the Indianapolis 500 on May 26, 2019. MannKind is an associate sponsor of Andretti...
Feb 26, 2019 08:00 am ET
MannKind Corporation Fourth Quarter and Year-End 2018 Earnings Call
MannKind Corporation (NASDAQ:MNKD) today reported financial results for the fourth quarter and full year ended December 31, 2018. Fourth Quarter Results For the fourth quarter of 2018, total revenues were $16.0 million, reflecting Afrezza net...
Feb 20, 2019 05:00 pm ET
MannKind Presents New Scientific Data at 12th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2019)
MannKind Corporation (Nasdaq:MNKD) today announced additional positive Afrezza clinical data to be presented in an oral presentation on Thursday, February 21, 2019 and a poster on Wednesday, February 20, 2019 at the 12th International Conference...
Feb 20, 2019 09:00 am ET
MannKind Corporation Participating at Upcoming Conferences
MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, announced today that it will be...
Feb 19, 2019 04:31 pm ET
MannKind Corporation to Hold 2018 Fourth Quarter and Full Year Financial Results Conference Call on February 26, 2019
MannKind Corporation (Nasdaq:MNKD) will release its 2018 fourth quarter and full year financial results on Tuesday, February 26, 2019 and its management will host a conference call to discuss the financial results and other Company developments at...
Feb 05, 2019 08:00 am ET
Market Trends Toward New Normal in MannKind, IDEX, Belden, Bright Horizons Family Solutions, Masonite International, and Veritiv — Emerging Consolidated Expectations, Analyst Ratings
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of MannKind Corporation (NASDAQ:MNKD), IDEX Corporation (NYSE:IEX), Belden...
Jan 16, 2019 04:30 pm ET
MannKind Announces Direct Purchase Insulin Program Providing Afrezza® for as low as $4 a Day
MannKind Corporation (Nasdaq:MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, today announced a direct purchase...
Dec 27, 2018 08:00 am ET
MannKind Corporation to Hold Investor Conference Call
MannKind Corporation (NASDAQ: MNKD) will host a conference call on Friday, January 4, 2019 to discuss Company developments at 9:00 AM (Eastern Time). Presenting from the Company will be its Chief Executive Officer, Michael Castagna.    To...
Dec 19, 2018 11:57 pm ET
MannKind Announces Pricing of $40 Million Public Offering
MannKind Corporation (Nasdaq: MNKD) (MannKind) today announced the pricing of an underwritten public offering of 26,666,667 shares of its common stock and warrants to purchase up to an aggregate of 26,666,667 shares of its common stock.  Each share...
Dec 19, 2018 04:01 pm ET
MannKind Announces Commencement of Public Offering
MannKind Corporation (Nasdaq: MNKD) (MannKind) today announced that it has commenced an underwritten public offering to issue and sell shares of its common stock and warrants to purchase shares of its common stock. The offering is subject to market...
Nov 27, 2018 09:00 am ET
MannKind Appoints Christine Mundkur to its Board of Directors
MannKind Corporation (Nasdaq: MNKD) today announced that Christine Mundkur has joined its Board of Directors, effective November 27, 2018.  Ms. Mundkur will also serve as a member of the Audit Committee of the Board. Ms. Mundkur brings 25 years of...
Nov 01, 2018 08:00 am ET
MannKind Corporation Reports 2018 Third Quarter Financial Results
MannKind Corporation (NASDAQ:MNKD) today reported financial results for the third quarter ended September 30, 2018. “In 3Q 2018, we executed on both of our corporate value drivers, Afrezza and Technosphere Platform, by signing a global licensing...
Oct 25, 2018 05:00 pm ET
MannKind Corporation to Hold 2018 Third Quarter Financial Results Conference Call on November 1, 2018
MannKind Corporation (Nasdaq: MNKD) will host a conference call to discuss the 2018 third quarter and year-to-date financial results and other corporate developments at 9:00 AM (Eastern Time) on Thursday, November 1, 2018. Presenting from the...
Oct 24, 2018 07:20 am ET
Research Report Identifies Cato, Roadrunner Transportation, Talend S.A, Vi, MannKind, and Acceleron Pharma with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Cato Corporation (NYSE:CATO), Roadrunner Transportation Systems, Inc...
Oct 16, 2018 06:00 am ET
United Therapeutics And MannKind Announce Closing Of License And Collaboration Agreement
RESEARCH TRIANGLE PARK, N.C. and WESTLAKE VILLAGE, Calif., Oct. 16, 2018 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) and MannKind Corporation (Nasdaq: MNKD) today announced the closing of their pending worldwide exclusive license and collaboration agreement for the development and commercialization of Treprostinil Technosphere®, a dry powder formulation of treprostinil being developed for the treatment of pulmonary arterial hypertension. As previously announced, the effectiveness of the agreement was conditioned upon expiration or termination of the required waiting period
Oct 16, 2018 06:00 am ET
United Therapeutics and MannKind Announce Closing of License and Collaboration Agreement
United Therapeutics Corporation (Nasdaq: UTHR) and MannKind Corporation (Nasdaq: MNKD) today announced the closing of their pending worldwide exclusive license and collaboration agreement for the development and commercialization of Treprostinil...
Oct 15, 2018 09:00 am ET
Afrezza® Inhaled Insulin Television Advertising Campaign Wins Gold Award for Creativity
MannKind Corporation (Nasdaq:MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, was recently awarded top honors for its...
Oct 04, 2018 09:00 am ET
MannKind Presents Positive Afrezza® STAT Study Clinical Data at 54th Annual Meeting of the European Association for the Study of Diabetes
MannKind Corporation (Nasdaq:MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, presented data from the STAT study...
Oct 03, 2018 09:00 am ET
MannKind Presents New Scientific Data at 54th Annual Meeting of the European Association for the Study of Diabetes
MannKind Corporation (Nasdaq:MNKD), announced that it presented new scientific data in an oral and poster presentation at the 54th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Berlin, Germany. The oral presentation...
Sep 24, 2018 09:00 am ET
MannKind Announces Completion of Cohort 1 and Opens Enrollment for Cohort 2 of Afrezza® Safety and Pharmacokinetics Study in Pediatric Patients
MannKind Corporation (Nasdaq:MNKD) announced today that Cohort 2 of the Afrezza® safety and pharmacokinetics study in pediatric patients is now open for enrollment. The first group of individuals participating in the ongoing pediatric study of...
Sep 13, 2018 09:00 am ET
Positive Afrezza® Clinical Data from STAT Study Published in Diabetes Technology & Therapeutics
MannKind Corporation (Nasdaq:MNKD) announced today that "Improved Postprandial Glucose with Inhaled Technosphere® Insulin Compared to Insulin Aspart in Patients with Type 1 Diabetes on Multiple Daily Injections: The STAT Study" has been published...
Sep 04, 2018 06:00 am ET
United Therapeutics And MannKind Announce Collaboration For Pulmonary Hypertension Products
SILVER SPRING, Md. and WESTLAKE VILLAGE, Calif., Sept. 4, 2018 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) and MannKind Corporation (Nasdaq: MNKD) today announced that they have entered into a worldwide exclusive licensing and collaboration agreement for the development and commercialization of a dry powder formulation of treprostinil, an investigational product currently being evaluated in clinical trials for the treatment of pulmonary arterial hypertension.
Sep 04, 2018 06:00 am ET
United Therapeutics and MannKind Announce Collaboration for Pulmonary Hypertension Products
United Therapeutics Corporation (Nasdaq: UTHR) and MannKind Corporation (Nasdaq: MNKD) today announced that they have entered into a worldwide exclusive licensing and collaboration agreement for the development and commercialization of a dry powder...
Aug 29, 2018 09:00 am ET
MannKind Corporation to Present at Upcoming Conferences
MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, announced today that it will present at...
Aug 28, 2018 07:30 am ET
Analysis: Positioning to Benefit within MannKind, Chimerix, Superior Energy Services, Marinus Pharmaceuticals, Airgain, and Eagle Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidate
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of MannKind Corporation (NASDAQ:MNKD), Chimerix, Inc. (NASDAQ:CMRX), Superior...
Aug 02, 2018 04:00 pm ET
MannKind Corporation Reports 2018 Second Quarter Financial Results Conference Call to Begin Today at 5:00 PM ET
MannKind Corporation (NASDAQ:MNKD) today reported financial results for the second quarter ended June 30, 2018. “In 2Q 2018, we experienced our highest Afrezza sales ever due to increased physician trial and adoption. We have doubled our...
Jul 27, 2018 02:03 pm ET
MannKind Corporation to Hold 2018 Second Quarter Financial Results Conference Call on August 2, 2018
MannKind Corporation (Nasdaq: MNKD) will host a conference call to discuss the 2018 second quarter and year-to-date financial results and other corporate developments at 5:00 PM (Eastern Time) on Thursday, August 2, 2018. Presenting from the...
Jul 27, 2018 09:37 am ET
MannKind and Tanner Pharma Group Enter into an ex-U.S. Distribution Agreement for Afrezza®
MannKind Corporation (Nasdaq:MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, today announced a distribution agreement...
Jul 27, 2018 09:00 am ET
MannKind and Tanner Pharma Group Enter into an ex-U.S. Distribution Agreement for Afrezza®
MannKind Corporation (Nasdaq:MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, today announced a distribution agreement...
Jul 27, 2018 09:00 am ET
MannKind Corporation to Hold 2018 Second Quarter Financial Results Conference Call on August 2, 2018
MannKind Corporation (Nasdaq: MNKD) will host a conference call to discuss the 2018 second quarter and year-to-date financial results and other corporate developments at 5:00 PM (Eastern Time) on Thursday, August 2, 2018. Presenting from the...
Jun 29, 2018 08:30 am ET
Factors of Influence in 2018, Key Indicators and Opportunity within MannKind, Healthcare Services Group, Cadence, Superior Energy Services, National Presto Industries, and New Media Investment Group —
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of MannKind Corporation (NASDAQ:MNKD), Healthcare Services Group, Inc....
Jun 25, 2018 09:00 am ET
MannKind Set to Join Russell 3000® Index
MannKind Corporation (Nasdaq:MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, today announced it is set to join the...
Jun 25, 2018 08:00 am ET
Additional Positive Afrezza® Clinical Data from STAT Study To Be Presented at ADA 78th Scientific Sessions
MannKind Corporation (Nasdaq:MNKD) announced that additional data for Afrezza from the STAT study (STudy comparing prandial insulin Aspart vs. Technosphere insulin in patients with Type 1 diabetes on multiple daily injections) will be presented in...
Jun 23, 2018 10:00 am ET
MannKind Presents Positive Afrezza® Clinical Data from STAT and AFFINITY Studies at ADA 78th Scientific Sessions
MannKind Corporation (Nasdaq:MNKD) announced that new data for Afrezza from the STAT study (STudy comparing prandial insulin Aspart vs. Technosphere insulin in patients with Type 1 diabetes on multiple daily injections) were released today at the...
Jun 20, 2018 04:01 pm ET
MannKind to Host Institutional Investor and Analyst Meeting
MannKind Corporation (Nasdaq:MNKD) today announced that it will host an invitation-only luncheon at Lotte New York Palace on Wednesday, June 27, 2018 for institutional investors and analysts, also accessible by live webcast (details below).  This...
Jun 07, 2018 09:00 am ET
MannKind Successfully Completes Phase 1 Trial of Treprostinil Technosphere for Pulmonary Arterial Hypertension Advancing Development to Next Phase
MannKind Corporation (Nasdaq:MNKD) today announced that it has completed a Phase 1 clinical study of Treprostinil Technosphere (TreT) under an Investigational New Drug application filed with the Food and Drug Administration. The key highlights of...
Jun 05, 2018 04:30 pm ET
MannKind Establishes Market Price Stock Purchase Plan
MannKind Corporation (NASDAQ:MNKD) has established a stock purchase plan that provides MannKind’s directors and executive officers with a way to purchase shares of common stock directly from the Company at the prevailing market price at the time of...
May 17, 2018 08:00 am ET
Detailed Research: Economic Perspectives on Churchill Downs, Nordic American Tankers, News Corporation, Aduro Biotech, MannKind, and Crane — What Drives Growth in Today's Competitive Landscape
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Churchill Downs, Incorporated (NASDAQ:CHDN), Nordic American Tankers...
May 09, 2018 04:01 pm ET
MannKind Corporation Reports 2018 First Quarter Financial Results
MannKind Corporation (NASDAQ:MNKD) today reported financial results for the first quarter ended March 31, 2018. “We started 2018 with solid growth of 184% in quarterly Afrezza sales year-over-year, which reflects our progression as a...
May 09, 2018 09:00 am ET
MannKind and Cipla Enter an Exclusive Marketing and Distribution Agreement for Afrezza® in India
MannKind Corporation (Nasdaq:MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, today announced an exclusive marketing...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.